Statement: the only case of congestive heart failure in the primary clinical trial emerged in cohort 2.
Primary_evidence: Adverse Events 1:   Total: 1/35 (2.86%)   congestive heart failure *1/35 (2.86%) Adverse Events 2:   Total: 0/40 (0.00%)   congestive heart failure *0/40 (0.00%)